Skip to main content

Table 3 Soluble and insoluble amyloid-beta levels measured by ELISA

From: Transition from an M1 to a mixed neuroinflammatory phenotype increases amyloid deposition in APP/PS1 transgenic mice

  Soluble (pg/μg protein) Insoluble (pg/μg protein)
AAV injection Survival (months) Aβ1-38 Aβ1-40 Aβ1-42 Aβ1-38 Aβ1-40 Aβ1-42
GFP-AAV 4 1.67 ± 0.77 2.97 ± 0.28 12.90 ± 2.24 9.04 ± 1.99 98.70 ± 36.77 903.27 ± 56.1
GFP-AAV 6 3.16 ± 0.75 5.10 ± 0.44 25.37 ± 3.81 23.82 ± 2.83 335.53 ± 64.95 1634.87 ± 397.9
IFNγ-AAV 4 3.68 ± 0.23 5.41 ± 0.91 27.17 ± 4.94 20.56 ± 8.48 295.78 ± 87.63 2855.26 ± 1267.9
IFNγ-AAV 6 4.95 ± 0.51 6.57 ± 0.89 38.90 ± 7.35 27.10 ± 4.10 269.72 ± 55.2 2047.32 ± 436.0
  1. Bold indicates P < 0.05 compared to GFP-AAV at the same time point. Aβ, amyloid-beta; AAV, adeno-associated virus; ELISA, enzyme-linked immunosorbent assay; IFN, interferon.